BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 7931486)

  • 1. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia.
    Reinisch W; Willheim M; Hilgarth M; Gasché C; Mader R; Szepfalusi S; Steger G; Berger R; Lechner K; Boltz-Nitulescu G
    J Clin Oncol; 1994 Oct; 12(10):2146-52. PubMed ID: 7931486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular expression and serum circulating levels of CD23 in B-cell chronic lymphocytic leukemia. Implications for prognosis.
    Molica S; Levato D; Dell'Olio M; Matera R; Minervini M; Dattilo A; Carotenuto M; Musto P
    Haematologica; 1996; 81(5):428-33. PubMed ID: 8952156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic importance of soluble CD23 in B-cell chronic lymphocytic leukemia.
    Saka B; Aktan M; Sami U; Oner D; Sanem O; Dinçol G
    Clin Lab Haematol; 2006 Feb; 28(1):30-5. PubMed ID: 16430457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia.
    Sarfati M; Chevret S; Chastang C; Biron G; Stryckmans P; Delespesse G; Binet JL; Merle-Beral H; Bron D
    Blood; 1996 Dec; 88(11):4259-64. PubMed ID: 8943862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia.
    Beguin Y; Lampertz S; De Groote D; Igot D; Malaise M; Fillet G
    Leukemia; 1993 Dec; 7(12):2019-25. PubMed ID: 8255102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia.
    Knauf WU; Langenmayer I; Ehlers B; Mohr B; Adorf D; Nerl CH; Hallek M; Zwingers TH; Emmerich B; Thiel E
    Leuk Lymphoma; 1997 Nov; 27(5-6):523-32. PubMed ID: 9477135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble CD23 measurement by CBA: a convenient and reliable quantification method in chronic lymphocytic leukemia.
    Grelier A; Le Garff-Tavernier M; Nauwelaers F; Sarfati M; Merle-Beral H
    Cytometry B Clin Cytom; 2014 Mar; 86(2):91-7. PubMed ID: 24150841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia.
    Schwarzmeier JD; Shehata M; Hilgarth M; Marschitz I; Louda N; Hubmann R; Greil R
    Leuk Lymphoma; 2002 Mar; 43(3):549-54. PubMed ID: 12002758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of sIL2R, sCD23, sICAM-1, IL6 and sCD 14 serum levels in B-cell chronic lymphocytic leukemia.
    Callea V; Morabito F; Luise F; Piromalli A; Filangeri M; Stelitano C; Iacopino P; Nobile F; Brugiatelli M
    Haematologica; 1996; 81(4):310-5. PubMed ID: 8870374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferative response of B chronic lymphocytic leukemia lymphocytes stimulated with IL2 and soluble CD23.
    Brizard A; Morel F; Lecron JC; Dreyfus B; Brizard F; Barra A; Preud'homme JL
    Leuk Lymphoma; 1994 Jul; 14(3-4):311-8. PubMed ID: 7950920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lag times between lymphoproliferative disorder and clinical diagnosis of chronic lymphocytic leukemia: a prospective analysis using plasma soluble CD23.
    Kaaks R; Sookthai D; Łuczyńska A; Oakes CC; Becker S; Johnson T; Johansson A; Melin B; Sjöberg K; Trichopoulos D; Trichopoulou A; Lagiou P; Mattiello A; Tumino R; Masala G; Agnoli C; Boeing H; Aleksandrova K; Brennan P; Franceschi S; Roulland S; Casabonne D; de Sanjose S; Sánchez MJ; Huerta JM; Ardanaz E; Sala N; Overvad K; Tjønneland A; Halkjær J; Weiderpass E; Bueno-de-Mesquita HB; Vermeulen R; Peeters PH; Vineis P; Kelly RS; Khaw KT; Travis RC; Key TJ; Riboli E; Nieters A
    Cancer Epidemiol Biomarkers Prev; 2015 Mar; 24(3):538-45. PubMed ID: 25542829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic analysis of receptor-ligand pairs on B-cells in B-chronic lymphocytic leukemia.
    Gagro A; Dasić G; Sabioncello A; Rabatić S; Reckzeh B; Havemann K; Kardum I; Jacksić B; Vitale B
    Leuk Lymphoma; 1997 Apr; 25(3-4):301-11. PubMed ID: 9168440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia.
    Piñeyroa JA; Magnano L; Rivero A; Rivas-Delgado A; Nadeu F; Correa JG; Giné E; Villamor N; Filella X; Colomer D; López M; López-Oreja I; Costa D; Aymerich M; Beà S; López-Guillermo A; Campo E; Delgado J; Mozas P
    Hematol Oncol; 2022 Oct; 40(4):588-595. PubMed ID: 35611996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia.
    Molica S; Levato D; Cascavilla N; Levato L; Musto P
    Eur J Haematol; 1999 Feb; 62(2):117-22. PubMed ID: 10052715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
    Hallek M; Wanders L; Ostwald M; Busch R; Senekowitsch R; Stern S; Schick HD; Kuhn-Hallek I; Emmerich B
    Leuk Lymphoma; 1996 Aug; 22(5-6):439-47. PubMed ID: 8882957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evolution of chronic lymphocytic leukemia: predictive value of immunophenotype, soluble CD23 and morphology].
    Sarmientó MA; Palacios MF; Scolnik MP; Ramírez FR; Stanganelli C; Cabrera J; Chena CP; Arrossagaray G; Slavutsky IR; Bengió RM
    Medicina (B Aires); 2002; 62(4):305-12. PubMed ID: 12325485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia.
    Schwarzmeier JD; Hubmann R; Düchler M; Jäger U; Shehata M
    Leuk Lymphoma; 2005 Feb; 46(2):157-65. PubMed ID: 15621797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating levels of soluble CD23 reflect clinical and biological features of leukemic B-cell chronic lymphoproliferative disorders.
    Vinante F; Vassanelli A; Zanotti R; Nadali G; Krampera M; Vincenzi C; Morosato L; Chilosi M; Pizzolo G
    Int J Clin Lab Res; 1995; 25(4):189-94. PubMed ID: 8788546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of TNF, IL-6 and sCD23 correlate with changes in lymphocyte count in patients with B-cell chronic lymphocytic leukaemia receiving interferon-alpha therapy.
    Jewell AP; Worman CP; Giles FJ; Goldstone AH
    Leuk Lymphoma; 1997 Jan; 24(3-4):327-33. PubMed ID: 9156662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of alpha-interferon and steroids on CD23 expression and release in B-cell chronic lymphocytic leukemia.
    Pozzato G; de Paoli P; Franzin F; Tulissi P; Moretti M; Basaglia G; Santini GF
    Haematologica; 1994; 79(3):205-12. PubMed ID: 7926968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.